ACCESS Newswire (Tue, 3-Feb 7:30 AM ET)
Market Chameleon (Thu, 16-Oct 5:54 AM ET)
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
Mira Pharmaceuticals trades on the NASDAQ stock market under the symbol MIRA.
As of February 24, 2026, MIRA stock price climbed to $1.25 with 100,540 million shares trading.
MIRA has a beta of 2.06, meaning it tends to be more sensitive to market movements. MIRA has a correlation of 0.20 to the broad based SPY ETF.
MIRA has a market cap of $52.35 million. This is considered a Micro Cap stock.
The top ETF exchange traded funds that MIRA belongs to (by Net Assets): VXF, VTI.
MIRA has underperformed the market in the last year with a return of +13.6%, while the SPY ETF gained +15.8%. In the last 3 month period, MIRA fell short of the market, returning -10.1%, while SPY returned +4.6%. However, in the most recent 2 weeks MIRA has outperformed the stock market by returning +5.0%, while SPY returned -1.0%.
MIRA support price is $1.17 and resistance is $1.29 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MIRA shares will trade within this expected range on the day.
